The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...

( NewsNation) — Zepbound became the first drug approved by the Food and Drug Administration to treat obstructive sleep apnea ...

The FDA approved a new drug treatment for obstructive sleep apnea that improves the condition through weight loss. Sleep ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

The approval was based on the results of the SURMOUNT-OSA trial, which found patients had fewer breathing disruptions.

FDA approves Zepbound for obstructive sleep apnea in obese individuals Discover how this weight-loss drug reduces symptoms ...

“Zepbound promotes weight loss and has been shown to reduce apnea events,” Troxel noted. “For obese individuals with moderate to severe sleep apnea, this new treatment option may offer an ...

Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said ...

"Zepbound promotes weight loss and has been shown to reduce apnea events." About 30 million people suffer from sleep apnea in the U.S., Troxel told Fox News Digital. While the most common treatmen ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.